<b>Gapping up</b><br/><b>In reaction to strong earnings/guidance: </b>CHGG +15.6%, (also announces an agreement in principle to establish a multi-year renewable agreement with Ingram Content Group for Ingram to be responsible for purchasing all textbook inventory which Chegg will continue to market under its brand), SPWR +12.1% (also, First Solar and SunPower plan to partner to form joint YieldCo vehicle), FIVN +8.7%, PN +5.7%, PN +5.7%, RLGY +5.1%, NLS +5%, TOL +4.4%, CBRL +4.3%, CEQP +4.2%, BHP +4.1%, CBLI +3.9%, SF +3.7%, (Stifel Financial announces the acquisition of Sterne Agee), AGU +3.7%, HD +3.3%, DEPO +2.9%, ATRI +2.7%, CLDX +2.7%, ONDK +2%, GTLS +2%, DYAX +1.8%, WPC +1.8%, ESRX +1.4%, DDS +1.4%, EXAS +1.3%, KAMN +1.2%, GLDD +1.1%, BEE +1%, TXRH +0.9%, TRXC +0.8%<br/><br/><b>M&A news</b>: SF +3.7% (announced the acquisition of Sterne Agee for ~$150 mln; expected to be accretive to shareholder value when fully integrated; co also reported earnings), ALLT +1.2% (to acquire operations of Optenet), HBAN +0.9% (to purchase Macquarie Equipment Finance)<br/><br/><b>Other news:</b> OCLR +12.3% ( Soros Fund Management discloses 9.95% passive stake in 13G filing), CAPN +11.5% ( positive blog mention), APRI +10.6% ( Sarissa Capital discloses 17.64% active stake in 13D filing), FSLR +10.5% (First Solar and SunPower plan to partner to form joint YieldCo vehicle), BIOC +8.2% (cont strength), CYTX +6.5% (European Medicines Agency's Committee for Orphan Medicinal Products issued a positive opinion toward Cytori's application for an orphan drug designation for the new Scleroderma therapeutic ECCS-50), CBAY +6.2% (positive preliminary topline results from its Phase 2b clinical study of its lead product candidate, arhalofenate), IBIO +6.1% (still checking), ASML +3.6% (may be attributed to AIXG results), MEA +3.2% (has retained Gordian Group to assist with an overall review of its business strategies going forward), NBG +2.6% (EU accepts Greece initial proposal), JPM +2.6% (presents at Investor Day), CVEO +2.4% (wins ~$32 mln in new village contracts), EXAS +1.9% (Wisconsin Economic Development Corporation will provide tax credits of up to $9 million to EXAS as part of the cancer diagnostics company's ongoing growth in the state), LOW +1.7% (in symp with HD), PSTI +1.7% (still checking), SUNE +1.7% (provides 2015 MW outlook), INOV +1.6% (announces a multi-year expansion of its relationship with Walgreens)<br/><br/><b>Analyst comments: </b>ONCE +3.2% (initiated with a Overweight at JP Morgan), COH +2% (upgraded to Outperform from Perform at Oppenheimer), JCP +1.5% (reiterated as a Top Pick for 2015 at Piper Jaffray), FEYE +0.9% (target raised at FBR)<br/><br/><b>Gapping down</b><br/><b>In reaction to disappointing earnings/guidance:</b> ROSE -15.6%, LIQD -5.2%, PDLI -4.8%, DK -4.5%, AXTI -4.1%, WOR -4.1%, (announces the Co's outlook has changed since it was discussed in December's fiscal year 2015 second quarter earnings call; expects weaker third quarter results), WIN -3.8%, DAKT -3.6%, CYRN -3.3%, TRAK -3.1%, THC -3.1%, CLDT -3.1%, IPXL -3%, PLL -2.8%, ODP -2.4%, RCAP -2%, TREX -1.7%, ALKS -1.6%, FELE -1.5%, OKE -1.4%, AMT -1.4%, M -1.4%, ADC -1.1%, GPX -1.1%, DPZ -1%, PF -0.7%<br/><br/><b>Select gaming related names showing weakness after reports officials are looking into restricting Chinese tourists into Macau to ease overcrowding:</b> LVS -2.9%, WYNN -2.7%, MPEL -2.3%, MGM -1.6%<br/><br/><b>Other news:</b> ALKS -25.3% (announces topline results from a phase 1 clinical study of ALKS 7106 for the treatment of pain, also released earnings), RGSE -18.5% (announced $3.5 mln public offering of common stock and warrants to purchase common stock), TEP -5.3% ( announces the commencement of an underwritten public offering of 10 mln common units representing limited partner interests), BOOT -4.1% (announced the release of lock-up restriction, taking effect Feb. 25, 2015), AXTI -4.1% (co's Audit Committee has conducted an investigation of certain potential related-party transactions involving Davis Zhang, the Company's President, China Operations), XNCR -4% ( intends to offer and sell, subject to market and other conditions, up to 5.5 mln shares of its common stock), NNN -3.2% (filed a mixed securities shelf offering), HCN -2.9% (announces anticipated first quarter 2015 investment pipeline of ~$2.2 bln), LXRX -2.7% (announced the resignation of Brian P. Zambrowicz, Ph.D., EVP and Chief Scientific Officer), ACI -2.3% (cont weakness), TSEM -2% (modest pull back following yday's earnings strength), DAL -1% (AAL and DAL not interested in Skymark agreement, spokesman says)<br/><br/><b>Analyst comments: </b>S -3.6% (downgraded to Sell from Neutral at BTIG Research), VOD -2.9% (downgraded to Underperform at BofA/Merrill), BPT -1.8% (initiated with a Underweight at JP Morgan; tgt $40), HII -1.7% (downgraded to Underperform from Neutral at Credit Suisse), STJ -1.7% (downgraded to Underperform from Neutral at Credit Suisse), AAL -1.5% (downgraded to Market Perform from Outperform at Cowen), LSTR -1.1% (downgraded to Hold from Buy at Deutsche Bank), Z -1.1% (downgraded to Neutral from Outperform at Macquarie), NEM -1% (downgraded to Neutral from Overweight at HSBC Securities), SHAK -0.8% (initiated with a Neutral at JP Morgan; initiated with a Neutral at Goldman, tgt $36)<br/><br/><i>Allikas: Briefing.com</i>